-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Initiates Coverage On NewAmsterdam Pharma Co with Buy Rating, Announces Price Target of $42

Benzinga·06/17/2025 11:41:41
Listen to the news
Citigroup analyst Geoff Meacham initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy rating and announces Price Target of $42.